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Many pathogens, such as the agents of West Nile encephalitis and
plague, are maintained in nature by animal reservoirs and trans-
mitted to humans by arthropod vectors. Efforts to reduce disease
incidence usually rely on vector control or immunization of hu-
mans. Lyme disease, for which no human vaccine is currently
available, is a commonly reported vector-borne disease in North
America and Europe. In a recently developed, ecological approach
to disease prevention, we intervened in the natural cycle of the
Lyme disease agent (Borrelia burgdorferi) by immunizing wild
white-footed mice (Peromyscus leucopus), a reservoir host species,
with either a recombinant antigen of the pathogen, outer surface
protein A, or a negative control antigen in a repeated field
experiment with paired experimental and control grids stratified
by site. Outer surface protein A vaccination significantly reduced
the prevalence of B. burgdorferi in nymphal blacklegged ticks
(Ixodes scapularis) collected at the sites the following year in both
experiments. The magnitude of the vaccine’s effect at a given site
correlated with the tick infection prevalence found on the control
grid, which in turn correlated with mouse density. These data, as
well as differences in the population structures of B. burgdorferi in
sympatric ticks and mice, indicated that nonmouse hosts contrib-
uted more to infecting ticks than previously expected. Thus, where
nonmouse hosts play a large role in infection dynamics, vaccination
should be directed at additional species.
Borrelia u vector u Ixodes u Peromyscus u tick
O f 175 microbial species considered emerging pathogens forhumans, 75% are zoonotic, that is, maintained in nature by
animal reservoirs (1). Several of these human pathogens are
transmitted by arthropod vectors (2, 3). For most vector-borne
pathogens, no human vaccines exist; the main approach for
reducing the public’s risk for disease transmission is vector
control. Vaccines directed at animal reservoirs provide addi-
tional opportunities to intervene in natural cycles and reduce
disease risk by the criterion of number of infected vectors (4).
Successful vaccination would decrease the availability of infected
hosts to vectors, resulting in a lower proportion of vectors that
are infected, and thus, a lower probability of pathogen trans-
mission to humans.
We tested this hypothesis by using Lyme disease (LD), a
zoonotic bacterial disease of the northern hemisphere whose
etiologic agents are maintained by several vertebrate host species
(5). In the eastern United States humans acquire LD when an
infected Ixodes scapularis tick attaches and transmits the spiro-
chete Borrelia burgdorferi. The recent surge in the incidence of
LD, in the face of the commercial withdrawal of the human
vaccine and a general reluctance to apply pesticides, prompts
consideration of new approaches to reducing disease risk (6, 7).
Because nymphal I. scapularis cause the majority of LD cases
(8), lower disease incidence could be achieved by limiting the
overall nymphal abundance, by lowering nymphal infection
prevalence (i.e., the proportion of nymphs infected), or both (4).
With the second aim in mind, we vaccinated wild populations of
the white-footed mouse (Peromyscus leucopus), which is consid-
ered to be the main reservoir host species for B. burgdorferi in
eastern North America (9, 10). The strategy was to convert the
phenotypes of reservoir host populations from competent to
noncompetent for B. burgdorferi transmission to I. scapularis
larvae, thereby reducing the proportion of larvae that molt into
infectious nymphs.
We immunized mice with recombinant B. burgdorferi outer
surface protein A (OspA) (11, 12), which is the basis of a currently
available vaccine for dogs (13). B. burgdorferi commonly expresses
OspA in tick, but not mouse hosts, and consequently, OspA-
vaccinated mice, even infected ones, develop antibodies that kill B.
burgdorferi in the tick while it feeds (12, 14, 15). A study of our field
site revealed that.90% of white-footed mice were infected during
the larval host-seeking period and confirmed that these hosts rarely
had antibodies to OspA (16).
Although the main end-point of the study was infection
prevalence among nymphal ticks, the vaccine was targeted at an
abundant vertebrate host species, from whom some proportion
of nymphs would have obtained blood meals as larvae in the
preceding year. Larval I. scapularis are not host-specific and have
been found to feed on many vertebrate species (17). On the basis
of previous studies (18, 19), we anticipated that the impact of
vaccination on reducing nymphal infection prevalence would
correlate positively with the proportional role that mice play in
infecting larvae. In other words, a determinant of vaccine effect
would be the degree to which alternative hosts infect feeding
larvae. The extent to which this happened was a second end-
point of the study and was inferred from vaccination results, as
well as by comparing the population structure of B. burgdorferi
among tick and mouse populations.
Materials and Methods
Field Site. The study grids were located in a 1,400-hectare private
mixed hardwood forest in southern Connecticut, where LD is
common (7) (Fig. 4, which is published as supporting informa-
tion on the PNAS web site). From 1998 to 2003, periodic
sampling at our field site found nymphal infection prevalence to
vary from 23% to 50% at various locations and an average
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density at the peak nymphal host-seeking period (beginning of
June) to range from 0.16 to 0.55 nymphs per m2 as determined
by dragcloth sampling (J.I.T., unpublished data). Deer density
estimates have ranged from 25 to 120 deer per km2 (20). For each
experiment, we chose three sites that were large enough to
comprise two grids, one experimental and one control, that had
similar landscape features and other ecological factors, that
which were also separated by at least 100 m, based on the
estimated home range size for P. leucopus (21). Traps were
placed 12 m apart and in arrays of 93 9 (1998) or 123 12 (2001).
Rodent Trapping and Processing. The study protocol (no. 07596) was
approved by the Yale University Institutional Animal Care and
Utilization Committee. Aluminum Sherman live traps were baited
with peanut butter (1998) or crimped oats (2001). Traps were set
between 1500 and 1800 hours and checked between 0800 and 0900
hours the next day. Mice captured for the first time each trapping
period (i) were anesthetized with ketamine (150 mgykg), (ii)
received a uniquely numbered metal ear tag upon initial capture,
(iii) were examined for sex,mass, and number of attached larval and
nymphal ticks, (iv) bled of#150 ml from the retroorbital sinus, and
(v) vaccinated with a vaccine or control immunogen. Upon recov-
ery from anesthesia, mice were rehydrated and released at the point
of capture. The blood clot and serum were stored at 220°C. Mice
recaptured within the same trapping period were only weighed and
examined for ticks; mice recaptured during subsequent trapping
periods were processed as described. We trapped mice from early
June (1998 and 2001) to late August (1998) or early September
(2001). At each site mice were trapped for 2–4 nights per trapping
period, with a total of four trapping periods per site and'3 weeks
between consecutive trapping periods.
Immunizations. In 1998, mice were inoculated s.c. with either
nonlipidated recombinant fusion protein of OspA from strain N40
and recombinant GST (22) on vaccine grids or GST alone on
control grids. Both immunogens (provided by E. Frikig, Yale
University, New Haven, CT) were emulsified with Freund’s com-
plete adjuvant for initial immunizations and Freund’s incomplete
adjuvant for up to two boosters at 3- to 6-week intervals. In a
laboratory experiment, this protocol reduced transmission effi-
ciency by 48%, 92%, and 99%, respectively, for one, two, and three
doses of OspA, in comparison to GST (15). In 2001, mice were
inoculated s.c. no more than twice with either lipidated OspA
(provided by R. Huebner, Aventis-Pasteur, Paris) from strain B31
or GST, both delivered with monophosphoryl lipid A and synthetic
trehalose dicorynomycolate (Ribi Adjuvant System, Corixa, Seat-
tle); immunogen doses were 10 mg for the first immunization and
5mg for the second. Previous studies demonstrated cross-protection
with an OspA antigen derived from one strain against a variety of
other strains found in nature (23, 24).
Tick Collections. In 1999 and 2002, we sampled grids for host-
seeking nymphal I. scapularis ticks by drag sampling (25) from
late May to August with the aims to collect ticks in proportion
to their relative abundance and distribution on grids and to
maximize sample sizes for analysis of infection with B. burgdor-
feri. Ticks were stored either live in environmental chambers at
95% relative humidity until they were frozen and stored at
270°C (1999) or directly immersed in 70% ethyl alcohol (2002).
Antibody Assay. Enzyme immunosorbent assays (EIAs) were
performed with recombinant OspA lipoprotein from strain B31
(provided by S. Bergstro¨m, Umeå University, Umeå, Sweden) as
described (16). Sera from pathogen-free, laboratory-reared P.
leucopus (Peromyscus Stock Center, University of South Caro-
lina, Columbia) served as negative controls. Samples with optical
density (OD) readings at wavelength 450 nm .3 SD above the
mean of the negative controls were considered positive. The OD
value for each serum sample was normalized, as an antibody
index, by calculating its ratio to an OD value 2 SD below the
mean of the negative controls.
DNA Extraction and PCR. In the 1998–1999 study, total DNA was
extracted from pulverized ticks by using a DNeasy Tissue kit
(Qiagen, Valencia, CA) as described (26, 27) and from 50–100 ml
of mouse blood by using Bio101 FastPrep kit (Qbiogene). In 2002,
ticks were quartered, and DNA was extracted from both ticks and
mouse blood by using a DNeasy Tissue kit (27, 28). DNA extracts
from 1999 were screened by PCR with Borrelia genus-specific flaB
gene primers as described (29). During the course of the study, a
new Borrelia species, provisionally classified as Borrelia miyamotoi
(28), was discovered in I. scapularis (30). Remaining samples from
flaBPCR-positive tickswere then reanalyzed for the presence of the
new species by using p66 gene primers that discriminate between B.
burgdorferi and B. miyamotoi (28, 31). In 4 of 81 samples from
control grids and 5 of 82 samples from vaccine grids, B. miyamotoi
instead of B. burgdorferi was detected. Accordingly, nymphal in-
fection prevalence for all sites and grids were multiplied by a factor
of 0.95 (154y163) to adjust for the presence of B. miyamotoi. Tick
extracts from 2002 and blood extracts from 2001 were subjected to
quantitative multiplex real time (RT) PCR with differential probes
for the 16S rDNAs ofB. burgdorferi andB.miyamotoi. Forward and
reverse primers at 900 nM were, respectively, 59-GCTGTAAAC-
GATGCACACTTGGT and 59-GGCGGCACACTTAACACGT-
TAG. The corresponding dye-labeled probes at 200 nM were
6FAM-TTCGGTACTAACTTTTAGTTAA and VIC-CGG-
TACTAACCTTTCGATTA modified with a minor groove bind-
ing (MGB) protein (Applied Biosystems). The PCR conditions
were 50°C for 2 min and 95°C for 10 min, followed by 45 cycles of
95°C for 15 s and 63°C for 60 s. Samples that were positive for the
presence ofB. burgdorferiwere then subjected to a secondmultiplex
RT-PCR that identified B. burgdorferi genotypes on the basis of the
rrs-rrlA intergenic spacer sequence (27). MGB-modified probes
6FAM-AGCCTAATAAAACTATTTAATATCAATAATTT
and VIC-AGCTCTTTAATATTAAAAATTCAATACAC spe-
cifically identified genotype groups I and II (32, 33). Genotype
group III was determined by subtracting from the first RT-PCR
numbers the summed numbers for genotype groups I and II from
the second PCR. Forward and reverse primers were 59-
AAAACCAGTGTTATTTATGTAAGTTTAAGAGAAGTTT
and 59-CCCCCAAAATGACCTAAAATTAAGTCTA, and an-
nealing was at 62°C. The identities of genotype groups were
confirmed for random samples by direct sequencing of the products
on a CEQ 8000 capillary sequencer (Beckman Coulter) as de-
scribed (27). Of 71 samples identified as group III by the above
criterion, 68 (96%) were confirmed to contain a group III genotype
alone.
Statistical Analyses. We estimated mouse densities from capture-
mark-recapture data by using CAPTURE (34) and the Mh model,
which assumes heterogeneity in capture probabilities and uses a
jackknife procedure to estimate the population size for a trapping
period. A grid’s density ofmice was estimated as the average of four
trapping period estimates. For continuous variables we used stan-
dard parametric statistics, giving the mean 6 95% confidence
interval (CI). For proportionsweused twomethods: (i) exact aswell
as asymptotic Cochran–Mantel–Haenszel (C–M–H) odds ratio
(OR) procedures, which allow for comparison of replicated 2 3 2
tables where replicates are stratified by levels of a covariate, and (ii)
a linear regression approach, where continuous and categorical
independent variables were entered into the model to predict the
arcsine-transformed proportional data. Before analyzing combined
data from both experiments, we ascertained that there was no
significant variation in the response variable due to a study effect.
Statistical analyses were conducted with SPSS version 11 (SPSS,
Chicago) and STATXACT version 6 (Cytel, San Diego).
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Results
Study Design. We conducted separate controlled field experi-
ments in 1998–1999 and 2001–2002, trapping over a total area of
18 hectare of forest in Connecticut. Although sites, grid size, and
vaccine formulation varied between the two experiments, each
manipulation consisted of three replicates of paired experimen-
tal (OspA) and control (GST) trapping grids stratified by site.
After mice were captured, sampled, and immunized with OspA
or GST during the summers of 1998 and 2001, we compared the
prevalence of B. burgdorferi infection in nymphal ticks collected
from different treatment grids the following summers. In the
2001–2002 study we also (i) compared population structures of
B. burgdorferi in mice and ticks at vaccine and control grids and
(ii) determined the prevalence in ticks ofB.miyamotoi as another
measure of comparability of treatment grids.
A combined 928 mice were captured and immunized on
experimental and control grids for both studies. Trapping suc-
cess was 11.6% of 7,128 trap nights (1998) and 22.9% of 10,080
trap nights (2001). Average mouse densities per ha were 20 6 9
(1998) and 34 6 8 (2001). Mark-recapture data showed that 79
6 4% (1998) and 736 1% (2001) of the mouse population were
captured and vaccinated at least once; 68 6 16% (1998) and 57
6 7% (2001) were captured and vaccinated at least twice by the
last trapping period. Adverse effects of OspA vaccination on
mice were not detected. The average proportion of mice cap-
tured in a previous trapping period on vaccine and control grids,
respectively, was 65 6 11% and 68 6 8% (1998) and 65 6 3%
and 63 6 7% (2001), indicating no effect of the vaccine on
survival across both experiments during the study. There was
also no difference in the mean weight gain (gyday) between mice
at vaccine (0.062 6 0.014; n 5 177) and control grids (0.060 6
0.015; n 5 144) between receipt of first vaccination and next
capture at a mean of 28 d later in 2001. Recapture data also
suggest that very few mice (0.2% in 1998 and 0.6% in 2001) used
multiple grids.
Antibody Responses and Infections of Immunized Mice. Treatments
at the vaccine grids manipulated the reservoir competence of the
white-footed mice, as defined by the presence of serum anti-
bodies to OspA by EIA (Fig. 1). Mean EIA values for sera of
captured mice rose with each trapping period on vaccine grids,
but substantially less or not at all on control grids. By the last
trapping periods, 71 6 9% (1998) and 66 6 17% (2001) of
captured mice on vaccine grids had seroconverted to OspA,
respectively. For both studies overall, by the peak larval host-
seeking period, there was a seroconversion rate of 696 9%, and
a capture rate of 79 6 10%. Thus, an estimated 55 6 13% of all
mice on vaccine grids were immunized.
To assess the vaccine’s effectiveness in preventing new infections
ofmice after immunization in 2001, we assayedmice trapped during
periods 2–4 and carried out PCR analysis for the presence of B.
burgdorferi in the blood, an indication of a newly acquired infection
(35) (Table 1). Vaccination with OspA was associated with a
proportional reduction of 42 6 15% in the prevalence of B.
burgdorferi in the blood of mice on the grids in comparison to GST
immunization. The reduction was greatest at site 5.
Nymphal Infection Prevalence. At control grids the average prev-
alence of B. burgdorferi in nymphal ticks (number of infected
ticksynumber of tested ticks) was 32.5 6 10.0% (1999) and 38.6
6 12.0% (2002). These levels of nymphal infection prevalence
were similar to what had previously been observed in Connect-
icut (36) and New York (10, 37). Vaccination with OspA was
associated with a significant reduction in nymphal infection
prevalence on experimental grids in each of the two experiments
(Table 2). Without adjustment for the migration of uncaptured
infectious mice and alternative hosts, which would tend to
increase nymphal infections on vaccinated grids, the mean
reductions of the odds of infection on vaccinated grids were 19%
(1999) and 25% (2002). The area-to-perimeter ratio was 33%
greater for 2001–2002 grids than that of 1998–1999 grids; thus,
the greater vaccine effect noted in the second studymay be partly
the consequence of fewer immigrant hosts.
In contrast to the findings for B. burgdorferi, the prevalence of
nymphs infected with B. miyamotoi was comparable between
vaccinated and control grids in 2002. The prevalence of this other
Borrelia species was 7 of 113, 25 of 314, and 7 of 262 for GST grids
4–6, and 5 of 112, 9 of 54, and 13 of 260 for OspA grids 4–6
(C-M-H OR 5 1.31, 0.737–2.335; P 5 0.4). Against the predic-
tion of lower B. burgdorferi burdens per tick from observations
of partially immunized laboratory mice (14, 15), there was no
significant reduction in the number of spirochetes per infected
Table 1. B. burgdorferi-specific PCR assay of blood of mice
captured during trapping periods 2–4 in 2001
Grid vaccine
No. of P. leucopus mice
Site 4 Site 5 Site 6
Pos. Neg. Pos. Neg. Pos. Neg.
GST 36 167 19 109 14 104
OspA 28 236 9 131 14 154
OR* (CI) 0.55
(0.31–0.97)
0.39
(0.15–0.96)
0.68
(0.31–1.48)
C–M–H† (CI) 0.54 (0.36–0.79) P 5 0.002
Pos., positive; Neg., negative.
*OR for nymphal infection prevalence at OspA vaccination grid compared to
GST grid.
†C–M–H stratified x2 test (95% confidence limits) and two-sided P value.
Fig. 1. Anti-OspA antibody responses in recombinant OspA- and GST-
immunized Peromyscus leucopus populations at a Connecticut field site in
1998 (A) and 2000 (B). The histograms with 95% confidence interval error bars
indicate the antibody index by OspA enzyme immunoassay (left y axis) for each
group of mice by treatment, site, and trapping period. The dots indicate the
percentages of the serum samples in each group that exceeded the mean of
negative control sera in the EIA by 3 standard deviations (SD; right y axis). The
numbers of P. leucopus sampled each trapping period are given at the top of
each graph.
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tick: 9,2606 1,772 (n5 184) for OspA grids and 10,2526 1,688
(n 5 244) for GST grids in 2002. The effect of the vaccine was
to reduce the absolute number of infected ticks rather than to
lower the spirochete burden in individual infected ticks.
Although there was an overall lower prevalence of B. burgdorferi
in nymphs at OspA grids in comparison to GST grids, the magni-
tude of the response varied among sites (Table 2). The odds of
infection were reduced on average by 32% at combined sites 2 and
3 (1999) and 40% at combined sites 4 and 6 (2001), but there was
no or little difference in B. burgdorferi prevalence between treat-
ments at sites 1 (1999) and 5 (2002). The apparent lack of a vaccine
effect at two of six sites was not associated with lower antibody
responses to OspA immunization among mice at these sites. In
2001, the mean increases in OspA EIA optical density values per
mouse per day for OspA grids between first and second captures
were 0.042 6 0.008 (n 5 87), 0.041 6 0.009 (n 5 46), and 0.039 6
0.008 (n 5 44) for sites 4, 5, and 6, respectively.
Population Structure of B. burgdorferi in Mice and Ticks. To inves-
tigate the differences among sites in vaccine effect, we examined
the genotypes of B. burgdorferi strains at a polymorphic locus
between their 16S and 23S ribosomal RNA genes (27, 32). The
rationale was the findings of different population structures
among vertebrate taxa for LD Borrelia species in Europe (38)
and for B. burgdorferi in New York (39). In other words, the
strain structure of B. burgdorferi is an indicator of the relative
contributions of mice and other reservoir hosts to infecting
larvae (27). Reservoir host composition would be an important
determinant of the magnitude of a vaccine’s effect when the
immunization was directed only at one species.
Indeed, there was a difference between I. scapularis and P.
leucopus, which were collected or captured at control sites in
2001–2002, in the distributions of genotype groups I–III among
infected vectors and hosts (Table 3). In particular, there was a
relative paucity of group III strains in mice in comparison to ticks,
suggesting the contribution of alternative hosts that transmit rela-
tively more group III genotypes to larvae than do mice. The ratio
of groups I:II:III strains in ticks and mice were similar between
years. In ticks the average ratio was 1.1:0.6:1.0, whereas in mice, it
was 3.0:2.0:1.0. Because there was no effect of vaccination on
overall nymphal infection prevalence at site 5, we specifically
compared the prevalence of group III strains at site 5’s control grid
with group III prevalence at the combined control grids of sites 4
and 6. We found a higher proportion of group III strains in ticks at
the control grid of site 5 (34% of 105) than at combined sites 4 and
6 (23% of 171; x2 5 3.8, P 5 0.05). These data indicate that
nontargeted hosts, perhaps chipmunks and shrews (10), infected
proportionally more larvae at site 5 than at other sites, thus
accounting in part for the lack of a vaccination effect at that site.
An association between population structure and apparent
vaccine effect was also observed among nymphs collected in
2002. Although there was no discernible effect of vaccination on
the overall prevalence of B. burgdorferi in nymphs at site 5, there
was a significant difference by genotype group (Fig. 2). In
comparison to group II and III strains, group I strains, which are
associated with more severe infections of laboratory mice and
humans (33), and which was the most common group in mice at
our field site, were significantly lower in prevalence at OspA
grids at all sites in 2002. This was evidence that OspA immuni-
zation at all sites, including site 5, reduced the prevalence of B.
burgdorferi infection of those nymphs that fed as larvae on
white-footed mice, the target species for vaccination.
Interaction Effect of Vaccine and Mouse Density. Another gauge of
the contributions of different reservoir hosts to infecting larvae was
the relationship between mouse density and nymphal infection
prevalence (Fig. 3A). On control grids, mouse density and nymphal
infection prevalence were positively correlated, supporting the view
that mice are important reservoir hosts, but also indicating a strong
role of heterogeneity in host community composition among sites.
In contrast, OspA immunization reduced the correlation between
mouse density and nymphal infection prevalence. A linear regres-
sion with nymphal infection prevalence as the dependent variable
and mouse density and treatment as independent variables showed
a significant interaction effect [r25 0.82, F(8, 1)5 12.1; P5 0.008;
Fig. 3A], thus providing evidence for both the white-footedmouse’s
role in determining B. burgdorferi abundance and the vaccine’s
effect. The differences between sites in the distributions of B.
burgdorferi genotypes, notably, the inverse relationship between the
proportion of genotype group III and mouse density, was evidence
that the densities of alternative host reservoirs did not parallel
mouse densities by site.
Although the overall results confirm the choice of targeting mice
for vaccination, the data also show that alternative hosts play an
important role in pathogen maintenance, because where mouse
densities were relatively lower, nymphal infection prevalences were
Table 3. Distribution of B. burgdorferi genotype groups in mice
and nymphal ticks at combined sites
Speciesystudy
Genotype group by sequence
I II III
P. leucopus mice
1998–1999 11 8 4
2001–2002 10 6 3
I. scapularis ticks
1998–1999 26 11 25
2001–2002 57 37 51
C–M–H*
Species effect x2 7.00 df 2 p 5 0.03
Study effect x2 1.04 df 2 p 5 0.61
*C–M–H exact test with 10,000 Monte Carlo samples (STATXACT version 6, Cytel).
Table 2. Nymphal tick infection in vaccine field studies in 1998–1999 and 2001–2002
Vaccine for
P. leucopus
No. of I. scapularis nymphs infected with B. burgdorferi assayed by PCR
1999 sites 2002 sites
1 2 3 4 5 6
Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg.
GST 90 315 57 89 127 224 57 56 93 221 94 168
OspA 87 288 49 121 96 241 41 71 76 178 67 193
OR (95% CI) 1.06
(0.76–1.48)
0.63
(0.39–1.04)
0.70
(0.5–0.98)
0.57
(0.32–0.99)
1.01
(0.69–1.48)
0.62
(0.42–0.92)
C–M–H OR 0.81 (0.65–0.99) P 5 0.04 0.75 (0.59–0.95) P 5 0.02
Pos., positive; Neg., negative.
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still .20%. Furthermore, the vaccine’s impact at a site increased
with mouse density of the grid as well as the nymphal infection
prevalence in thematched control grid (Fig. 3B), another indication
that, where mice were more dense, they played a proportionately
larger role than alternative hosts in infecting larvae.
Discussion
Here we demonstrate that vaccination of wildlife reservoirs can
reduce vector infection prevalence, thus lowering the risk of patho-
gen transmission to humans. In two large-scale experiments, we
vaccinated nearly 1,000 white-footedmice, a species considered the
most important reservoir of B. burgdorferi in the northeastern
United States (9, 10). The number of replicates was restricted to
achieve a grid size that not only captured ecological dynamics and
heterogeneity on a realistic scale but also provided for sufficient
trapping periods for repeated vaccinations, all within a season’s
transmission period. Although the power of each experiment to
detect an effect of vaccination was limited, the results between the
two experiments were consistent, despite differences between
vaccine formulation, grid size, and grid location, and a combined
analysis confirmed trends found in each more limited experiment.
Over both field trials, 69 6 9% of the recaptured mouse
population, or an estimated 55 6 13% of all mice in each
experimental group, had seroconverted to OspA by the peak of
the larval host-seeking period. In the succeeding years, there was
an overall proportional reduction of 16 6 12% in the nymphal
infection prevalence at vaccine grids in comparison to control
grids (Table 2). The size of the reduction in nymphal infection
prevalence varied significantly with mouse density, nymphal
infection prevalence, and B. burgdorferi population structure,
evidence that host composition (i.e., mice vs. nonmouse)
strongly influenced local infection dynamics at the field location.
Nonmouse hosts, such as deer, squirrels, and raccoons, are
reportedly less competent than white-footed mice as reservoirs for
B. burgdorferi transmission to vector ticks (10). These and other
observations in both North America (18, 40, 41) and Europe (38,
42, 43) have led to a hypothesis about the importance of diverting
larval ticks away from their major reservoir host species to achieve
a lower nymphal infection prevalence. Our results are consistent
with that hypothesis: therewere direct relationships betweenmouse
density and nymphal infection prevalence and between the popu-
lation structure of B. burgdorferi, a proxy for evaluating reservoir
host contributions (39), and nymphal infection prevalence. Extra-
polation to the y intercept beyond the data range of Fig. 3 provides
an estimate that, under our experiment’s conditions, nymphal
infection would be reduced to '13% in the absence of mice but
presence of alternative hosts for larval ticks.
On the other hand, the results of this controlled experimental
intervention show that the contributions of alternative hosts to B.
burgdorferi maintenance cannot be ignored. The relative contribu-
tions of mice and alternative hosts to infecting larvae can be
estimated if, for this purpose, we assume linearity between the
proportion of mice that were vaccinated one year and nymphal
infection prevalence the next (15). If 55 6 13% vaccination
coverage by the last trapping period produced an overall reduction
Fig. 2. Distribution of group I (A), II (B), and III (C) B. burgdorferi genotype
groups among questing nymphs collected on GST control (open bars) and
OspA vaccine (shaded bars) grids in 2002. Numbers of nymphs assayed per grid
are listed within bars. OR and 95% CI given for the odds of a nymph being
infected with a given genotype on a vaccinated versus a control grid were
determined by an exact Cochran–Mantel–Haenzsel procedure for stratified
tables. Some nymphs were infected with twoB. burgdorferigenotype groups;
thus, the sum of the prevalence of genotype groups was greater than the
overall nymphal infection prevalence for some groups. Fig. 3. The relationship between mouse density, nymphal infection preva-
lence, and magnitude of vaccine effect. (A) The relationship between mouse
density (miceyha, hectare) and nymphal infection (inf.) prevalence. Dashed
lines represent 95% CI of the slope for the solid regression lines. The coeffi-
cient of determination (r2) is given for each treatment. Open and filled
symbols represent GST-immunized (control) and OspA-immunized grids, re-
spectively. Grids from the same site are represented by the same symbol: site
1, circle; site 2, square; site 3, inverted triangle; site 4, hexagon; site 5, triangle;
site 6, diamond. (B) Vaccine effect (1 2 OR) as a function of the control grid
nymphal infection prevalence (Table 1). The OR represents the odds of a
nymph being infected on a vaccinated grid versus on the control grid at the
same site. Symbols for sites are as indicated in A.
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of 16 6 12% in infections of nymphs, then with 100% vaccination
coverage under similar circumstances, nymphal infection preva-
lence would be predicted to be reduced by 27 6 21%. This value
also provides an estimate of the proportion of infected larvae that
can be attributed to mice alone, over the entire range of mouse
densities found at all sites. If we only consider site 4, which had the
highestmouse density and greatest vaccine effect (Fig. 3), we obtain
a maximum estimate for mouse contributions at our field site. The
predicted proportion of infected larvae attributable to transmission
from mice increases, but only to 55%. Although we recognize that
disease transmission dynamics may in fact be nonlinear, especially
at the extremes of reservoir host density, the results lead us to
conclude that alternative hosts probably have a greater role in
infecting larvae than most previous studies would predict. Accord-
ingly, for reducing disease risk for humans, we encourage increased
study of and emphasis on nonmouse hosts, including identification
of other critical species for infection maintenance.
The present study’s protocol of syringe delivery of the vaccine
would be impractical in a broader application, but oral delivery of
OspA, which was efficacious in protecting laboratory mice against
B. burgdorferi (22, 44), could be implemented and administered to
white-footed mice and, as indicated, to other reservoir species in
areas at high-risk for LD. The immunological response need not be
life-long; it need only be efficacious during the larval host-seeking
period, which is'2 months in the northeastern United States. The
successful application of oral recombinant rabies vaccine in food
bait in enzootic areas in the United States and Europe demon-
strates the feasibility as well as public and regulatory acceptance of
field vaccination against zoonoses (45, 46).
For LD and other vector-borne diseases, reduction in the risk of
transmission has relied mainly on vector control measures, such as
pesticide application and habitat modification. When commercial
human vaccines have been available for vector-borne zoonoses
(e.g., LD and RockyMountain Spotted Fever), they often have not
been sufficiently profitable or efficacious to remain on the market,
and even a successful vaccine targeted to humans would not reduce
the exposure risk for nonimmune individuals. Our study shows that
vaccination of a wild vertebrate reservoir population is feasible and
capable of reducing the prevalence of a vector-borne zoonotic
pathogen. Field vaccination of reservoirs then provides an addi-
tional control measure for inclusion in a risk-reduction program,
which might include a different mix of strategies, contingent upon
the particular ecological dynamics of the pathogen and various
social and political constraints on implementation. We further
propose that this approach may also be an effective component in
an integrated management program for other emerging and re-
emerging vector-borne zoonoses, such as plague through vaccina-
tion of sylvatic or urban rodents, andWestNile encephalitis through
vaccination of reservoir bird species.
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